article · Neurology

Efficacy and Safety of Efgartigimod in Myasthenia Gravis: A Systematic Review and Meta-analysis of Different Antibody Subtypes (P11-9.018)

Haneen Sabet
Dalia Kamal Ewis
Mohamed Ahmed Zanaty
Gergis Altalab
Abdullah Almarfadi
Basant Lashin
Ziyad Elyamany
Abdallah Khatatbeh
Hala Al-Rayess
Mohamed El-Moslemani
Abdallah Abbas

2026South Valley University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

To evaluate the efficacy and safety of efgartigimod in patients with myasthenia gravis (MG) and to determine whether response differs between AChR-positive and AChR-negative subtypes.

Research topics

Myasthenia Gravis and Thymoma
Coagulation, Bradykinin, Polyphosphates, and Angioedema
Sphingolipid Metabolism and Signaling

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1212/wnl.0000000000216868

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.